TriSalus Life Sciences In-Date & Expired
TriSalus Life Sciences is transforming regional cancer treatment with innovative technologies designed to improve drug delivery to solid tumors. At the core of TriSalus’ platform is the TriNav™ Infusion System, a next-generation tool engineered for Pressure-Enabled Drug Delivery™ (PEDD™)—a proprietary method that enhances therapeutic uptake by overcoming high interstitial pressure in solid tumors.
The TriNav™ Infusion System enables precise intravascular administration of immunotherapeutics and chemotherapy agents directly to diseased tissue, making it especially effective for treating primary and metastatic liver tumors, pancreatic cancer, and other hard-to-treat abdominal cancers. With its smart design and compatibility with standard interventional radiology techniques, TriNav™ supports optimized delivery to the tumor microenvironment while reducing systemic exposure.
TriSalus’ integrated approach pairs PEDD™ technology with regional immunotherapy strategies, addressing immune suppression within the tumor microenvironment and unlocking new potential for checkpoint inhibitors and other immunotherapies. With a growing clinical pipeline and ongoing trials across leading cancer centers, TriSalus Life Sciences is committed to improving outcomes in patients with unresectable or treatment-resistant tumors.